查看文章

Context.—Although the long-term health benefits of good glycemic control in patients with diabetes are well documented, shorter-term quality of life (QOL) and economic savings generally have been reported to be minimal or absent. Objective.—To examine short-term outcomes of glycemic control in type 2 diabetes mellitus (DM). Design.—Double-blind, randomized, placebo-controlled, parallel trial. Setting.—Sixty-two sites in the United States. Participants.—A total of 569 male and female volunteers with type 2 DM. Intervention.—After a 3-week, single-blind placebo-washout period, participants were randomized to diet and titration with either 5 to 20 mg of glipizide gastrointestinal therapeutic system (GITS)(n= 377) or placebo (n= 192) for 12 weeks. Main Outcome Measures.—Change from baseline in glucose and hemoglobin A1c (HbA1c) levels and symptom distress, QOL, and health economic indicators by questionnaires and diaries. Results.—After 12 weeks, mean (±SE) HbA1c and fasting …